Relevant bibliographies by topics / CNS drugs / Books
To see the other types of publications on this topic, follow the link: CNS drugs.

Books on the topic 'CNS drugs'

Author: Grafiati
Published: 4 June 2021
Last updated: 5 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'CNS drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

International Bioanalytical Forum (6th 1985 University of Surrey). Bioactive analytes: Including CNS drugs, peptides, and enantiomers. New York: Plenum Press, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Reid, Eric, Bryan Scales, and Ian D. Wilson, eds. BIOACTIVE ANALYTES, Including CNS Drugs, Peptides, and Enantiomers. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4757-1892-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

McArthur, Robert A., and Franco Borsini. Animal and translational models for CNS drug discovery. Amsterdam: Elsevier/Academic Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kalali, Amir, Joseph Kwentus, Sheldon Preskorn, and Stephen M. Stahl, eds. Essential CNS Drug Development. Cambridge: Cambridge University Press, 2012. http://dx.doi.org/10.1017/cbo9780511977640.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Essential CNS drug development. Cambridge: Cambridge University Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schreiber, Rudy, ed. Modern CNS Drug Discovery. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-62351-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Borsook, David, Lino R. Beccera, Edward Bullmore, and Richard J. Hargreaves, eds. Imaging in CNS Drug Discovery and Development. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-1-4419-0134-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Atta-ur-Rahman and M. Iqbal Choudhary, eds. Frontiers in CNS Drug Discovery Volume 3. UAE: Bentham Science Publishers Ltd., 2017. http://dx.doi.org/10.2174/97816810844351170301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ces drôles de médicaments. Paris: Delagrange, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Concise clinical pharmacology: CNS therapeutics. New York: McGraw-Hill, Medical Pub. Division, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Principles of CNS drug development: From test tube to patient. Chichester, West Sussex: J. Wiley, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Kelly, John. Principles of CNS drug development: From test tube to patient. Chichester, UK: Wiley-Blackwell, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Kelly, John. Principles of CNS drug development: From test tube to patient. Chichester, West Sussex: J. Wiley, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Atta-ur-Rahman, ed. Frontiers in Clinical Drug Research - CNS and Neurological Disorders Volume 5. UAE: Bentham Science Publishers Ltd., 2017. http://dx.doi.org/10.2174/97816810858521170501.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Wick, Steve. Bad company: Drugs, Hollywood, and the Cotton Club murder. San Diego: Harcourt, Brace, Jovanovich, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Silvay, Peluso Lucy, ed. Women & drugs: Getting hooked, getting clean. Minneapolis, Minn: CompCare Publishers, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

Jean-Pierre, Cartier, ed. Ces drogués qui ont vaincu la drogue. Paris: Plon, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Cartier, Rachel. Ces drogués qui ont vaincu la drogue. Montréal, Qué: Guérin, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

Pétry, François. L' industrie pharmaceutique et les lois C-22 et C-91 étude de cas. [Québec, Quebec: Université Laval], 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

Ahmad, Nadya. Canadian addiction survey (CAS): A national survey of Canadians' use of alcohol and other drugs : focus on gender. [Ottawa, Ont.]: Health Canada, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

Full committee hearing on Medicaid drug reimbursements: Are CMS cuts bad medicine for small businesses and beneficiaries? Washington: U.S. G.P.O., 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

Falardeau, Marlène. Dans les tripes de la drogue et de la violence: Mieux comprendre ces jeunes. Québec (Québec): Presses de l'Université du Québec, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

Abdo, K. NTP technical report on the toxicology and carcinogenesis studies of Roxarsone (CAS no. 121-19-7) in F344/N rats and B6C3F1 mice (feed studies). Research Triangle Park, NC: National Toxicology Program, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

R, Cutler Neal, ed. Accelerating CNS drug development. Chichester: John Wily & Sons, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
25

Kurtz, Neil M., John J. Sramek, Angelico Carta, Neal R. Cutler, and Michael F. Murphy. Accelerating CNS Drug Development. Wiley & Sons, Incorporated, John, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
26

Kurtz, Neil M., John J. Sramek, Angelico Carta, Neal R. Cutler, and Michael F. Murphy. Accelerating CNS Drug Development. John Wiley & Sons, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

Reid, E. "Bioactive Analytes, Including Cns Drugs, Peptides, and Enantiomers". Springer, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

Translational Neuroimaging Tools For Cns Drug Discovery Development And Treatment. Academic Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

Imaging In Cns Drug Discovery And Development Implications For Disease And Therapy. Springer, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

(Editor), Michael Bradbury, David Begley (Editor), and Jorg Kreuter (Editor), eds. The Blood-Brain Barrier and Drug Delivery to the CNS. Informa Healthcare, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Di, Li, and Edward H. Kerns. Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. Wiley & Sons, Incorporated, John, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

Di, Li, and Edward H. Kerns. Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. Wiley & Sons, Incorporated, John, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

Di, Li, and Edward H. Kerns. Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. Wiley & Sons, Limited, John, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
34

Dickenson, Tony. Endogenous opioids in the CNS. Edited by Paul Farquhar-Smith, Pierre Beaulieu, and Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0019.

Full text
Abstract:
This short and concise paper was the first to unequivocally reveal that there were endogenous opioids in the central nervous system (CNS), identify their peptide nature and sequence, and show that they exerted physiological inhibitory effects. The idea that there were natural opioids fitted with concurrent reports of opiate-binding sites, and this led to the description of multiple receptors with their own families of peptide transmitters. No truly novel opioid drugs have emerged since, and attempts to protect and manipulate the enkephalins for pain control have yet to be successful. This does not detract from this key study, which made us think about pain modulation in a different way, and subsequent work has clearly shown how endogenous opioid signalling is critical in CNS function, perhaps most importantly in endogenous pain control, such as that harnessed by placebo analgesia.
APA, Harvard, Vancouver, ISO, and other styles
35

R, Cutler Neal, ed. Critical pathways to success in CNS drug development. Chichester, UK: Wiley-Blackwell, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
36

Sramek, John J., Neal R. Cutler, Michael F. Murphy, Henry Riordan, and Peter Biek. Critical Pathways to Success in CNS Drug Development. Wiley & Sons, Incorporated, John, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
37

Critical pathways to success in CNS drug development. Chichester, UK: Wiley-Blackwell, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

Sramek, John J., Neal R. Cutler, Michael F. Murphy, Henry Riordan, and Peter Biek. Critical Pathways to Success in CNS Drug Development. Wiley & Sons, Limited, John, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
39

Bioactive Analytes, Including CNS Drugs, Peptides, and Enantiomers (Methodological Surveys in Biochemistry & Analysis, Vol 16). Springer, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
40

Matthew, Verderame, ed. CRC Handbook of CNS agents and local anesthetics. Boca Raton, Fla: CRC Press, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
41

Keefe, Richard S. E., Avi (Abraham) Reichenberg, and Jeffrey Cummings, eds. Cognitive Enhancement in CNS Disorders and Beyond. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190214401.001.0001.

Full text
Abstract:
This book compiles a series of educational and thought-provoking chapters from the world's leading cognitive and clinical scientists to describe the latest research on cognitive impairments in a host of pathological conditions that affect CNS functioning, the available treatments for these impairments, and how new treatments are being tested. This volume advances the field toward the availability of cognitive enhancing drugs and devices that will benefit those who need them most and others who may believe that these techniques can help them to thrive. Psychological science and cognitive neuroscience have become the most popular endeavor of students worldwide, are the focus of attention of our greatest scientific accomplishments, and are the emphasis of many publications in the mainstream media. Because humans depend on cognitive abilities for survival, quality of life, and productivity, improving them has never been more important. Those with impairments in key aspects of cognition suffer dearly because they are unable to obtain and retain information, unable to make sound decisions based on the information at hand, and unable to plan future activities. The availability of pharmacological and behavioral interventions that can improve cognitive abilities and provide impaired individuals with the social, occupational, and functional quality of life that the rest of us enjoy has potential far-reaching implications. Such interventions can also benefit those who want to boost current cognitive abilities to higher levels, perhaps as a means to hone skills in providing products for others or to gain an edge on competition.
APA, Harvard, Vancouver, ISO, and other styles
42

Devlin, Hugh, and Rebecca Craven. Central nervous system. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198759782.003.0012.

Full text
Abstract:
The central nervous system (CNS) in relation to dentistry is the topic of this chapter. Nerve conduction is described, then the physiology of facial and dental pain and processing of afferent pain nerve impulses in the cerebral cortex. We discuss abnormal sensations of allodynia and paraesthesia. Pain control with non-steroidal anti-inflammatory drugs or paracetamol is explained. The function of the cranial nerves and the autonomic nervous system are described. We explain the nerve pathways involved in salivation, lachrymation, and taste sensation. We propose some techniques for treating the nervous patient, e.g. modelling, systematic desensitization, and feedback. Effective local anaesthesia is essential in gaining the cooperation of nervous patients. The major types of local anaesthetics are compared. The techniques for inferior alveolar and superior alveolar nerve blocks are described as are drugs commonly used in dental sedation. There are final sections on drug problems encountered in dental practice and on dementia.
APA, Harvard, Vancouver, ISO, and other styles
43

Cannon, Joseph G. Advances in Cns Drug Receptor Interactions (Advances in CNS Drug-receptor Interactions). Jai Pr, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
44

Atta-ur-Rahman, Bentham Science Publisher, and M. Iqbal Choudhary, eds. Frontiers in CNS Drug Discovery. BENTHAM SCIENCE PUBLISHERS, 2013. http://dx.doi.org/10.2174/97816080576721130201.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Atta-ur-Rahman and M. Iqbal Choudhary, eds. Frontiers in CNS Drug Discovery. BENTHAM SCIENCE PUBLISHERS, 2012. http://dx.doi.org/10.2174/97816080515951100101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Translational Medicine in CNS Drug Development. Elsevier, 2019. http://dx.doi.org/10.1016/c2014-0-03886-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Krueger, Darcy A., and Jamie Capal. Familial CNS Tumor Syndromes. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0136.

Full text
Abstract:
Tuberous sclerosis complex is an autosomal dominant multi-system disease that involves the skin, brain, heart, lungs, and kidneys and is associated with seizures including infantile spasms, intellectual disability, autism and pulmonary and heart disease. Skin lesions can be particularly disfiguring and infantile spasms can be associated with marked cognitive decline. The outlook for patients has improved markedly with the recognition that TSC is caused by upregulation of the mammalian target of rapamycin (mTOR) enzyme, which connects energy needs and supply with cellular and neuronal growth. mTOR is upregulated in TSC because of mutations in hamartin or tuberin, which normally serve as a brake on mTOR. The drug rapamycin is commonly used as an immunosuppressive for patients undergoing kidney transplants; it has also found a new use in patients with TSC. Although the drug is immunosuppressive for non-TSC patients, careful titration of the drug in TSC patients corrects its upregulation but is not particulary immunosuppressive. Additional mTOR inhibitors such as everolimus have been developed and have been shown to be effective for pulmonary disease associated with TSC. Rapamycin in ointment form is dramatically effective in suppressing skin lesions of TSC and studies are underway to test the effect of mTOR inhibitors on seizures, brain tubers, intellect, and features of autism. Infantile spasms associated with TSC are very responsive to vigabatrin.
APA, Harvard, Vancouver, ISO, and other styles
48

Pagnoux, Christian, and Richard H. Swartz. Vasculitis of the Central Nervous System. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0099.

Full text
Abstract:
Central nervous system (CNS) vasculitis is an extremely challenging diagnostic and therapeutic disease. Multiple conditions, including reversible cerebral vasoconstrictive syndrome and intracranial atherosclerosis, can mimic it. Infections, systemic diseases, particularly systemic vasculitides, drug abuse, neoplasms, and some other disorders can cause secondary CNS vasculitis. Primary CNS vasculitis is extremely rare. A definite diagnosis requires a brain biopsy, which may show granulomatous inflammation, lymphocytic inflammation, and/or acute necrotizing vasculitis. The pathogeny remains unknown. The treatment of secondary CNS vasculitis relies on that of its cause, whereas treatment for primary CNS vasculitis is not codified but usually relies on high-dose glucocorticoids, combined, at least for the most severe forms, with an immunosuppressant, mainly cyclophosphamide.
APA, Harvard, Vancouver, ISO, and other styles
49

Cannon, J. G. Advances in CNS Drug-Receptor Interactions, Volume 1. Jai Pr, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
50

G, Cannon Joseph, ed. Advances in CNS Drug-receptor interactions: A research annual. Greenwich, Conn: JAIPress, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'CNS drugs' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography